322 related articles for article (PubMed ID: 29902579)
21. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
Choi J; Jung WH; Koo JS
Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray.
He J; Peng R; Yuan Z; Wang S; Peng J; Lin G; Jiang X; Qin T
Med Oncol; 2012 Jun; 29(2):406-10. PubMed ID: 21264529
[TBL] [Abstract][Full Text] [Related]
23. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
24. Association between androgen receptor status and prognosis in triple negative breast cancer.
Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the Androgen Receptor in Older Women with Primary Breast Cancer: Association with a Panel of Biomarkers and Breast Cancer Specific Survival.
Kalvala J; Parks RM; Abdi J; Green AR; Cheung KL
Adv Ther; 2023 Jun; 40(6):2820-2835. PubMed ID: 37118159
[TBL] [Abstract][Full Text] [Related]
26. Expression of androgen receptors in triple negative breast carcinomas.
Mrklić I; Pogorelić Z; Capkun V; Tomić S
Acta Histochem; 2013 May; 115(4):344-8. PubMed ID: 23031358
[TBL] [Abstract][Full Text] [Related]
27. Prognostic markers in triple-negative breast cancer.
Rakha EA; El-Sayed ME; Green AR; Lee AH; Robertson JF; Ellis IO
Cancer; 2007 Jan; 109(1):25-32. PubMed ID: 17146782
[TBL] [Abstract][Full Text] [Related]
28. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.
Tozbikian GH; Zynger DL
Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800
[TBL] [Abstract][Full Text] [Related]
29. Imaging features of triple-negative breast cancers according to androgen receptor status.
Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
[TBL] [Abstract][Full Text] [Related]
30. L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.
Doberstein K; Milde-Langosch K; Bretz NP; Schirmer U; Harari A; Witzel I; Ben-Arie A; Hubalek M; Müller-Holzner E; Reinold S; Zeimet AG; Altevogt P; Fogel M
BMC Cancer; 2014 Dec; 14():958. PubMed ID: 25510351
[TBL] [Abstract][Full Text] [Related]
31. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Riaz N; Idress R; Habib S; Lalani EN
Front Oncol; 2020; 10():1083. PubMed ID: 32850312
[No Abstract] [Full Text] [Related]
32. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
33. Androgen Receptor in Stage I-II Primary Breast Cancer -Prognostic Value and Distribution in Subgroups.
Niméus E; Folkesson E; Nodin B; Hartman L; Klintman M
Anticancer Res; 2017 Dec; 37(12):6845-6853. PubMed ID: 29187464
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor expression identifies patient with favorable outcome in operable triple negative breast cancer.
Hu XQ; Chen WL; Ma HG; Jiang K
Oncotarget; 2017 Aug; 8(34):56364-56374. PubMed ID: 28915596
[TBL] [Abstract][Full Text] [Related]
35. Triple-Negative Breast Cancer: A Comprehensive Study of Clinical, Histomorphological, and Immunohistochemical Features in Indian Patients.
Sable M; Pai TD; Shet T; Patil A; Dhanavade S; Desai SB
Int J Surg Pathol; 2017 May; 25(3):230-237. PubMed ID: 27612858
[TBL] [Abstract][Full Text] [Related]
36. Expression and clinical significance of androgen receptor in triple negative breast cancer.
Luo X; Shi YX; Li ZM; Jiang WQ
Chin J Cancer; 2010 Jun; 29(6):585-90. PubMed ID: 20507730
[TBL] [Abstract][Full Text] [Related]
37. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer.
Thike AA; Yong-Zheng Chong L; Cheok PY; Li HH; Wai-Cheong Yip G; Huat Bay B; Tse GM; Iqbal J; Tan PH
Mod Pathol; 2014 Mar; 27(3):352-60. PubMed ID: 23929266
[TBL] [Abstract][Full Text] [Related]
38. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of treatment outcomes of triple-negative breast cancer.
Cinkaya A; Akin M; Sengul A
J Cancer Res Ther; 2016; 12(1):150-4. PubMed ID: 27072229
[TBL] [Abstract][Full Text] [Related]
40. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers.
Safarpour D; Tavassoli FA
Arch Pathol Lab Med; 2015 May; 139(5):612-7. PubMed ID: 25310144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]